Pdfs/Index.Php)
Total Page:16
File Type:pdf, Size:1020Kb
2016–2017 ANCER C ON ESEARCH R FOR GENCY A ONAL I NTERNAT I BIENNIAL REPORT 2016–2017 INTERNATIONAL AGENCY FOR RESEARCH ON CANCER l l Tél. 04 78 19 16 16 16 16 19 78 04 Tél. Saint-Martin-en-Haut 69850 : impression et graphique Conception 16/17 SC/54/2 GC/60/2 BIENNIAL REPORT 2016–2017 INTERNATIONAL AGENCY FOR RESEARCH ON CANCER LYON, FRANCE 2017 The cover depicts the growing global cancer burden. Each human figure represents 0.5 million persons. The estimated number of new cancer cases worldwide in 2012 (14.1 million) is based on data from GLOBOCAN 2012. The predicted number of new cases in 2035 (29.4 million) takes into account both population projections and changes in the incidence rates of the major cancers worldwide. © IARC/Morena Sarzo ISBN 978-92-832-1103-7 ISSN 0250-8613 © International Agency for Research on Cancer, 2017 150, Cours Albert Thomas, 69372 Lyon Cedex 08, France Distributed on behalf of IARC by the Secretariat of the World Health Organization, Geneva, Switzerland TABLE OF CONTENTS Introduction ......................................................................................................................................................... 1 Scientific Structure ............................................................................................................................................. 3 IARC Medals of Honour ...................................................................................................................................... 4 Section of Cancer Surveillance ......................................................................................................................... 7 Section of Evidence Synthesis and Classification ......................................................................................... 15 IARC Monographs Group ............................................................................................................................. 16 IARC Handbooks Group ............................................................................................................................... 18 WHO/IARC Classification of Tumours Group ............................................................................................ 19 Section of Mechanisms of Carcinogenesis ..................................................................................................... 23 Epigenetics Group ........................................................................................................................................ 24 Molecular Mechanisms and Biomarkers Group ........................................................................................ 28 Section of Molecular Pathology ........................................................................................................................ 33 Section of Infections ........................................................................................................................................... 39 Infections and Cancer Biology Group ........................................................................................................ 40 Infections and Cancer Epidemiology Group .............................................................................................. 41 Section of Environment and Radiation ............................................................................................................ 45 Section of Nutrition and Metabolism ................................................................................................................ 51 Biomarkers Group ......................................................................................................................................... 52 Dietary Exposure Assessment Group ........................................................................................................ 54 Nutritional Epidemiology Group .................................................................................................................. 54 Nutritional Methodology and Biostatistics Group .................................................................................... 56 Section of Genetics ............................................................................................................................................ 59 Genetic Epidemiology Group ....................................................................................................................... 60 Genetic Cancer Susceptibility Group ......................................................................................................... 62 Section of Early Detection and Prevention ...................................................................................................... 67 Prevention and Implementation Group ....................................................................................................... 68 Screening Group ........................................................................................................................................... 70 Office of the Director .......................................................................................................................................... 75 Communications Group ..................................................................................................................................... 77 Education and Training Group .......................................................................................................................... 81 Laboratory Services and Biobank Group ........................................................................................................ 89 The Gambia Hepatitis Intervention Study ........................................................................................................ 93 Section of Support to Research ........................................................................................................................ 95 Committees .......................................................................................................................................................... 99 Laboratory Steering Committee .................................................................................................................. 99 Biobank Steering Committee ....................................................................................................................... 99 Computational Biology, Bioinformatics, and Biostatistics Steering Committee .................................. 010 Ethics Committee .......................................................................................................................................... 010 Occupational Health and Safety Committee .............................................................................................. 010 Governing and Scientific Councils ................................................................................................................... 110 Staff Publications ................................................................................................................................................ 910 Collaborators ....................................................................................................................................................... 141 Acknowledgements ............................................................................................................................................ 149 © WHO/Ricardo Martinez WHO/Ricardo © INTRODUCTION By necessity, this Biennial Report include courtesy, honesty, generosity, Uruguay in Montevideo in October 2017, presents just a selection of the research integrity, and independence – all easy I was struck by the political will that offers conducted by the International Agency to write down but demanding to display. remarkable opportunities for tackling for Research on Cancer (IARC) during What is remarkable to witness is how a the growing burden of cancer and other the period 2016–2017. One of the most commitment to these values is returned NCDs on a global scale. In thinking about common questions about the Agency, manifold by our colleagues around the what IARC’s response to this challenge when the number of its scientists or the world. should be, I was drawn to the words size of its budget become known, is how of former United Nations Secretary- it manages to achieve all it does with The cancer burden continues to rise General Dag Hammarskjöld, who wisely such limited resources. The answer is globally. The increasing calls to move noted, “The ‘great’ commitment is so straightforward: the Agency does not from words to action are well justified, but much easier than the ordinary everyday work alone. True to its statute, it serves cancer control actions must be informed one.” This Biennial Report relates the to promote international collaboration by scientific evidence, provided through everyday efforts of IARC, accompanied in cancer research. Consequently, research. Research is needed about the by its many friends around the world, what you read about here is a product scale and patterns of cancer, and about to provide cancer research for cancer of cooperation. Perhaps surprisingly its causes, prevention, early detection, prevention. In this light, it is a pleasure in a field not unfamiliar with the drive and treatment. This research must be to commend the report to the reader for individual recognition, promoting multidisciplinary; it should stretch from in recognition